Search
for
Sort by
Research 151–180 of 777
- Psychological Stress-Induced Pathogenesis of Alopecia Areata: Autoimmune and Apoptotic Pathways
- Peripheral neuropathy associated with tofacitinib use in alopecia universalis
- Personalized Medicine in the Field of Inflammatory Skin Disorders
- Alopecia Areata of the Nails: Diagnosis and Management
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
- Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis
- Atopic Dermatitis and Multilocular Alopecia Areata Simultaneously Treated With Baricitinib
- Abrocitinib in the Treatment of Severe Alopecia Areata in a Pediatric Patient: A Case Report
- 056 IL-15 prolongs hair growth and operates as a guardian of human hair follicle immune privilege
- FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
- A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
- Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
- Rapidly progressive alopecia areata totalis in a COVID‐19 patient, unresponsive to tofacitinib
- Abrocitinib Treatment in Diffuse Alopecia Areata: A Case Report and a Literature Review
- Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience
- Treatment of concomitant alopecia areata and systemic lupus erythematosus with ivarmacitinib: a case report and literature review
- Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
- Hair regrowth in alopecia areata and re‐pigmentation in vitiligo in response to treatment: Commonalities and differences
- Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
- Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
- Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata